ELORES: A NOVEL TREATMENT APPROACH IN ELECTRIC BURN PATIENT WITH BACTEREMIA AND VENTILATOR-ASSOCIATED PNEUMONIA: A CASE STUDY

Authors

  • Sunny Rupal

Abstract

ABSTRACT
Rising challenge in treating nearly a million burn patients in India, with high mortality and morbidity attributed to nosocomial infections, is a
serious concern. With cascades of reactions taking place in serious burn patients, there is a massive release of humoral factors, such as cytokines,
prostaglandins, vasoactive prostanoids, and leukotrienes, along with multiple defects of cellular and humoral components of defense system. This
immunocompromised state favors increased chances of nosocomial infections such as pneumonia and blood stream infections. The present case
discusses a novel treatment approach with Elores (ceftriaxone, sulbactam, and adjuvant disodium edetate) in effectively treating burn patient with
bacteremia and ventilator-associated pneumonia.
Keywords: Bacteremia, Elores, Electric burns, Ventilator-associated pneumonia.

Downloads

Download data is not yet available.

References

REFERENCES

Huzar TF, Cross JM. Ventilator-associated pneumonia in burn patients:

A cause or consequence of critical illness? Expert Rev Respir Med

;5(5):663-73.

Fouzia B, Damle AS, Maher G. Changing patterns of burn infections.

IOSR J Dent Med Sci 2013;5(4):11-4.

Mayhall CG. The epidemiology of burn wound infections: Then and

now. Clin Infect Dis 2003;37(4):543-50.

Brusselaers N, Logie D, Vogelaers D, Monstrey S, Blot S. Burns,

inhalation injury and ventilator-associated pneumonia: Value of routine

surveillance cultures. Burns 2012;38(3):364-70.

Jeschke MG, Kamolz LP, Sjöberg F, Wolf SE. Handbook of Burns:

Acute Burn Care. Vol. 1. New York: Springer Wien; 2012. p. 227.

de La Cal MA, Cerdá E, García-Hierro P, Lorente L, SánchezConcheiro

M,

Díaz C,

et

al.

Pneumonia

in

patients

with

severe

burns:

A

classification according

to

the

concept

of

the carrier

state.

Chest

;119(4):1160-5.

Anvarinejad M, Japoni A, Rafaatpour N, Mardaneh J, Abbasi P, Amin

Shahidi M, et al. Burn patients infected with metallo-beta-lactamaseproducing

Pseudomonas

aeruginosa:

Multidrug-resistant strains.

Arch

Trauma

Res 2014;3(2):e18182.

Biswal I, Arora BS, Kasana D, Neetushree. Incidence of multidrug

resistant Pseudomonas aeruginosa isolated from burn patients and

environment of teaching institution. J Clin Diagn Res 2014;8(5):DC26-9.

Turner KH, Everett J, Trivedi U, Rumbaugh KP, Whiteley M.

Requirements for Pseudomonas aeruginosa acute burn and chronic

surgical wound infection. PLoS Genet 2014;10(7):e1004518.

D’Avignon LC, Murray CK. Fever in the burn patient. Infect Dis

Antimicrob Agents. Available from: http://www.antimicrobe.org/e44.

asp.

Azimi L, Motevallian A, Ebrahimzadeh Namvar A, Asghari B, Lari AR.

Nosocomial infections in burned patients in Motahari hospital, Tehran,

Iran. Dermatol Res Pract 2011;2011:436952.

Lee HG, Jang J, Choi JE, Chung DC, Han JW, Woo H, et al. Blood

stream infections in patients in the burn intensive care unit. Infect

Chemother 2013;45(2):194-201.

Luo J, Guo GH. Interpretation for practice guidelines for prevention,

diagnosis, and treatment of ventilator-associated pneumonia in burn

patients by American burn association. Burns Trauma 2015;3:11.

Avni T, Levcovich A, Ad-El DD, Leibovici L, Paul M. Prophylactic

antibiotics for burns patients: Systematic review and meta-analysis.

BMJ 2010;340:c241.

Chaudhary M, Payasi A. Ethylenediaminetetraacetic acid: A nonantibiotic

adjuvant

enhancing Pseudomonas

aeruginosa

susceptibility.

Afr

J Microbiol Res 2012;6(39):6799-804.

Chaudhary M, Payasi A. Incidence, prevalence and control of multidrug

resistant (MDR) carbapenemase producing Acinetobacter baumanii in

Indian intensive care units. J Pharm Res 2013;7(2):175-80.

Arora S, Munshi N. Comparative assessment of antibiotic susceptibility

pattern of Gram-negative pathogens isolated from intensive care unit

patients in Pune. Br Microbiol Res J 2015;10(2):1-9.

Chaudhary M, Payasi A. Clinical, microbial efficacy and tolerability

of Elores, a novel antibiotic adjuvant entity in ESBL producing

pathogens: Prospective randomized controlled clinical trial. J Pharm

Res 2013;7(4):275-80.

Jain A. Acute left lung abscess caused by multidrug-resistant

Pseudomonas aeruginosa treated with Elores: A case study. Int J Adv

Res 2015;3(7):173-6.

Chaudhary M, Payasi A. Susceptibility trend of drugs among

metallo β-lactamase producing strains of Escherichia coli, Klebsiella

pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa

in India. Int J Adv Pharm Biol Chem 2015;4(2);303-12.

Chaudhary M, Payasi A. Inhibition of metallo beta-lactamases by

Elores. J Antimicrob Photonics 2013;128:177-82.

Goyal S. Management of pneumonia with multiloculated left pleural

effusion caused by extended spectrum beta-lactamases producing

Klebsiella pneumoniae. Int J Clin Biomed Res 2015;1(4):73-6.

Gupta N. A case study: Viral pneumonia induced acute respiratory

distress syndrome with super infection of ESBL producing Klebsiella

pneumonia treated with antibiotic adjuvant entity: Elores. Int J Adv Res

;3(8):136-9.

Published

01-03-2016

How to Cite

Rupal, S. “ELORES: A NOVEL TREATMENT APPROACH IN ELECTRIC BURN PATIENT WITH BACTEREMIA AND VENTILATOR-ASSOCIATED PNEUMONIA: A CASE STUDY”. Asian Journal of Pharmaceutical and Clinical Research, vol. 9, no. 2, Mar. 2016, pp. 13-15, https://journals.innovareacademics.in/index.php/ajpcr/article/view/10753.

Issue

Section

Case Study(s)